article thumbnail

SCOTUS’ abortion pill mifepristone case is really about the FDA

STAT

WASHINGTON — The Supreme Court on Tuesday will hear opening arguments in an abortion medication case that pharmaceutical companies warn could upend the industry and paralyze new drug development.

article thumbnail

AI to revolutionise drug development by 2026

European Pharmaceutical Review

Initial data from the CPHI Annual Report 2023, which provides insight from 250 global pharmaceutical companies, reveals that AI (artificial intelligence) is expected to transform every area of the industry, from drug discovery through to drug development , within the next 24-months. Attending CPHI Barcelona 2023?

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Pursuing new paths in targeted protein degradation drug development

European Pharmaceutical Review

DRUG DEVELOPMENT based on targeted protein degradation (TPD) has progressed rapidly since the publication in 2015 of three landmark papers 1-3 that highlighted important early-stage breakthroughs with drug-like molecules in this area of research.

article thumbnail

STAT+: A ‘blank check’: Bill to boost antibiotic development blasted as a ‘flawed’ giveaway to pharma

STAT

The legislation, known as the Pasteur Act, would encourage drug development by creating a subscription-style business model in which the U.S. The idea is to enable pharmaceutical companies to recover their costs and make an appropriate profit without having to sell large volumes of antibiotics.

article thumbnail

Top U.S. addiction researcher calls GLP-1 data for addiction ‘very, very exciting’

STAT

Early data regarding the use of GLP-1 medications like Ozempic and Wegovy to treat addiction is “very, very, exciting,” Nora Volkow, the director of the National Institute on Drug Abuse, said Thursday. drug crisis with urgency.

article thumbnail

Using RWE in rare disease drug development: effective innovations with historical controls

European Pharmaceutical Review

Rare disease drug development poses unique challenges that can be overcome by using real-world evidence (RWE). These assessments often need to involve comparisons against multiple alternative therapies that would be impractical in the context of a clinical drug development. Regulatory and payer guidance.

article thumbnail

STAT+: Animal rights group urges SEC to investigate Charles River over monkey purchases

STAT

A leading animal rights group has asked securities regulators to investigate Charles River Laboratories for allegedly misleading investors about its sales and purchases of long-tailed macaques, which are widely used in clinical research by pharmaceutical companies and universities, among others.

Labelling 329